Caudron JM[au] - Search Results

Year	Number of Results
1999	1
2001	1
2004	1
2008	1
2013	1
2016	1
2017	1
2018	1
2024	0

1

Substandard medicines in resource-poor settings: a problem that can no longer be ignored.

Caudron JM, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J. Caudron JM, et al. Trop Med Int Health. 2008 Aug;13(8):1062-72. doi: 10.1111/j.1365-3156.2008.02106.x. Epub 2008 Jul 8. Trop Med Int Health. 2008. PMID: 18631318 Free article. Review.

2

Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy.

Ravinetto R, Vandenbergh D, Macé C, Pouget C, Renchon B, Rigal J, Schiavetti B, Caudron JM. Ravinetto R, et al. Among authors: caudron jm. J Pharm Policy Pract. 2016 Nov 10;9:36. doi: 10.1186/s40545-016-0088-0. eCollection 2016. J Pharm Policy Pract. 2016. PMID: 27843547 Free PMC article.

3

Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries.

Van Assche K, Nebot Giralt A, Caudron JM, Schiavetti B, Pouget C, Tsoumanis A, Meessen B, Ravinetto R. Van Assche K, et al. Among authors: caudron jm. BMJ Glob Health. 2018 Jun 9;3(3):e000771. doi: 10.1136/bmjgh-2018-000771. eCollection 2018. BMJ Glob Health. 2018. PMID: 29915671 Free PMC article.

4

The global impact of Indian generics on access to health.

Ravinetto RM, Dorlo TP, Caudron JM, Prashanth NS. Ravinetto RM, et al. Among authors: caudron jm. Indian J Med Ethics. 2013 Apr-Jun;10(2):118-20. doi: 10.20529/IJME.2013.035. Indian J Med Ethics. 2013. PMID: 23697493 Free article. No abstract available.

5

Quality assurance of medicines supplied to low-income and middle-income countries: poor products in shiny boxes?

Nebot Giralt A, Schiavetti B, Meessen B, Pouget C, Caudron JM, Marchal B, Massat P, Thys S, Ravinetto R. Nebot Giralt A, et al. Among authors: caudron jm. BMJ Glob Health. 2017 Mar 29;2(2):e000172. doi: 10.1136/bmjgh-2016-000172. eCollection 2017. BMJ Glob Health. 2017. PMID: 28589013 Free PMC article.

6

Public health. Responding to market failures in tuberculosis control.

Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE, Raviglione MC. Gupta R, et al. Among authors: caudron jm. Science. 2001 Aug 10;293(5532):1049-51. doi: 10.1126/science.1061861. Epub 2001 Jul 19. Science. 2001. PMID: 11463877 No abstract available.

7

Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.

Ashokraj Y, Agrawal S, Varma MV, Singh I, Gunjan K, Kaur KJ, Bhade SR, Kaul CL, Caudron JM, Pinel J, Panchagnula R. Ashokraj Y, et al. Among authors: caudron jm. Int J Tuberc Lung Dis. 2004 Sep;8(9):1081-8. Int J Tuberc Lung Dis. 2004. PMID: 15455592

8

Requirements for anti-tuberculosis drug tender requests.

Trébucq A, Caudron JM, Pinel J. Trébucq A, et al. Among authors: caudron jm. Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S358-61; discussion S381-7. Int J Tuberc Lung Dis. 1999. PMID: 10593718

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year